Vera Therapeutics price target raised to $125 from $110 at H.C. Wainwright
H.C. Wainwright raised the firm's price target on Vera Therapeutics to $125 from $110 and keeps a Buy rating on the shares after the FDA granted accelerated approval to Trutakna with "a broad and clean label" to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. The target patien